![Javier Szwarcberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Javier Szwarcberg
Vorstandsvorsitzender bei
SPRUCE BIOSCIENCES, INC.
Vermögen: 974 335 $ am 31.05.2026
Profil
Javier Szwarcberg is Chief Executive Officer & Executive Director at Spruce Biosciences, Inc. since 2022.
Formerly, Dr. Szwarcberg was Group VP, Head-Product & Portfolio Development at BioMarin Pharmaceutical, Inc. from 2020 to 2022, Senior VP-Program & Portfolio Management at Ultragenyx Pharmaceutical, Inc. from 2017 to 2020, and Vice President-Clinical & Business Development at Horizon Therapeutics Ltd. (Ireland) from 2016 to 2017.
Education includes a doctorate from Universidad de Buenos Aires and graduate studies at Harvard T.H.
Chan School of Public Health.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 24.03.2026 | 19’004 ( 1.78% ) | 974 335 $ | 31.05.2026 |
Aktive Positionen von Javier Szwarcberg
| Unternehmen | Position | Beginn |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Vorstandsvorsitzender | 03.01.2022 |
Ehemalige bekannte Positionen von Javier Szwarcberg
| Unternehmen | Position | Ende |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01.01.2022 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01.02.2020 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2017 |
Ausbildung von Javier Szwarcberg
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
17
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
Horizon Therapeutics Ltd. (Ireland)
 Horizon Therapeutics Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Universidad de Buenos Aires
 Universidad de Buenos Aires Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard T.H. Chan School of Public Health
 Harvard T.H. Chan School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Spruce Biosciences, Inc.
 Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as biopharmaceutical company which develops novel therapies for endocrine diseases | Health Technology |
